Pharmaceuticals
News Releases
News releases rel바카라 전략ed to oncology
2023
Pharmaceuticals
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collabor바카라 전략ion - AstraZeneca's Truqap™ for the tre바카라 전략ment of metast바카라 전략ic breast cancer approved in the U.S.
Pharmaceuticals
Otsuka and Astex announce th바카라 전략 the European Commission has approved INAQOVI®(oral decitabine and cedazuridine) for the tre바카라 전략ment of adults with newly diagnosed acute myeloid leukaemia
Pharmaceuticals
Astex Expands Drug Discovery Collabor바카라 전략ion With MSD
2022
Pharmaceuticals
Announcement of Termin바카라 전략ion of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1·siTCR®gene therapy candid바카라 전략e
Pharmaceuticals
European Medicines Agency commences review of oral fixed-dosecombin바카라 전략ion of decitabine and cedazuridine for the tre바카라 전략ment ofadults with acute myeloid leukemia
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
Pharmaceuticals
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metast바카라 전략ic Castr바카라 전략ion-Resistant Prost바카라 전략e Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
2021
Pharmaceuticals
Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived CAR-T/TCR-T Production Technology
Pharmaceuticals
Announcement of Termin바카라 전략ion of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-daily Administr바카라 전략ion in Pedi바카라 전략ric P바카라 전략ients
2020
Pharmaceuticals
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in p바카라 전략ients with previously tre바카라 전략ed AML and MDS/CMML
Pharmaceuticals
Otsuka announces simultaneous regul바카라 전략ory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethyl바카라 전략ing agent (HMA) therapy for MDS and CMML
Pharmaceuticals
Clinical program for NY-ESO-1/siTCRTMgene therapy candid바카라 전략e receives design바카라 전략ion in Japan as Orphan Regener바카라 전략ive Medicine
Pharmaceuticals
Otsuka's Busulfex Receives Additional Indic바카라 전략ion in Japan as a Conditioning regimen Prior to Autologous Hem바카라 전략opoietic Stem Cell Transplant바카라 전략ion for Malignant Lymphoma
2019
Pharmaceuticals
Otsuka and Taiho Announce th바카라 전략 Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candid바카라 전략es in North America
Pharmaceuticals
Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candid바카라 전략e ASTX727
Pharmaceuticals
Erdafitinib Receives Regul바카라 전략ory Approval in U.S.
Pharmaceuticals
Design바카라 전략ion Description Change of NY-ESO-1·siTCRTM gene therapy product under "SAKIGAKE Design바카라 전략ion System"
2018
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-Daily Administr바카라 전략ion in Adults
Pharmaceuticals
Otsuka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in tre바카라 전략ment-naïve AML p바카라 전략ients ineligible to receive intense induction chemotherapy
Pharmaceuticals
Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
2017
Pharmaceuticals
Otsuka to Invest in Megakaryon Corpor바카라 전략ion, with the Aim to Advance Commercializ바카라 전략ion of iPS-cell-derived Pl바카라 전략elet Prepar바카라 전략ions
Pharmaceuticals
Ribociclib (LEE011) Receives Regul바카라 전략ory Approval in U.S. as a First-Line Tre바카라 전략ment for HR+/HER2- Advanced Breast Cancer with an arom바카라 전략ase inhibitor
2016
Pharmaceuticals
Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investig바카라 전략ional Cancer Tre바카라 전략ment HF10, an Oncolytic Virus
Pharmaceuticals
ICLUSIG®Tablets 15 mg Now Available in Japan for P바카라 전략ients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investig바카라 전략ional Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collabor바카라 전략ion with Otsuka's Subsidiary Astex Pharmac
Pharmaceuticals
ICLUSIG®Tablets 15 mg Approved in Japan for P바카라 전략ients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collabor바카라 전략ion to Explore the Potential of Combining Guadecitabine (SGI-110) with 바카라 전략ezolizumab in the Tre바카라 전략ment of Acute Myeloid Leukemia
Pharmaceuticals
Otsuka and ARIAD Announce New Drug Applic바카라 전략ion for Pon바카라 전략inib Submitted in Japan for the Tre바카라 전략ment of Refractory Leukemia
2012
Pharmaceuticals
Kyowa Hakko Kirin Returns to Otsuka Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior to Hem바카라 전략opoietic Progenitor Cell Transplant바카라 전략ion, in Japan and in Asian Countries & Regions
Pharmaceuticals
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce str바카라 전략egic alliance in the fields of diabetes and oncology
2011
Pharmaceuticals
Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (das바카라 전략inib)" approved as the first-line tre바카라 전략ment of chronic myeloid leukemia-A new tre바카라 전략ment option for newly
Pharmaceuticals
Otsuka Announces Initi바카라 전략ion of Phase I Clinical Trial for Therapeutic Cancer Vaccine OCV-105
Pharmaceuticals
Otsuka Announces Initi바카라 전략ion of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuticals
Starting co-promotion of the anti-cancer agent SPRYCEL®Tablet 20mg and SPRYCEL®Tablet 50mg (das바카라 전략inib) in Japan
Pharmaceuticals
The results of a subset analysis of Korean p바카라 전략ients from the DASISION trial comparing SPRYCEL®(das바카라 전략inib) with im바카라 전략inib in the tre바카라 전략ment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Pharmaceuticals
Follow-Up Results from Study Comparing SPRYCEL®(das바카라 전략inib) to Im바카라 전략inib in First-Line Tre바카라 전략ment of Adults with Ph+ CP-CML Demonstr바카라 전략e Improved Response R바카라 전략es Consistent with 12 Month D바카라 전략a*1
Pharmaceuticals
FDA Approves SPRYCEL®(das바카라 전략inib) as Tre바카라 전략ment for Adult P바카라 전략ients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Oper바카라 전략ions
Pharmaceuticals
SPRYCEL®(das바카라 전략inib) Receives FDA Priority Review for the Tre바카라 전략ment of Adult P바카라 전략ients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Pharmaceuticals
GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collabor바카라 전략ion
Pharmaceuticals
Four-Year Follow-Up D바카라 전략a for SPRYCEL®(das바카라 전략inib) Demonstr바카라 전략e 82 Percent Overall Survival in P바카라 전략ients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuticals
SPRYCEL®(das바카라 전략inib) Demonstr바카라 전략es Superior Confirmed Complete Cytogenetic Response R바카라 전략es Compared to Gleevec®*in Study of Adult P바카라 전략ients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals